AU Patent

AU2021277638A1 — Cnp prodrugs with carrier attachment at the ring moiety

Assigned to Ascendis Pharma Endocrinology Division AS · Expires 2021-12-23 · 4y expired

What this patent protects

The present invention relates to CNP prodrugs in which the carrier is covalently and reversibly attached to the ring moiety of a CNP moiety, to pharmaceutical compositions comprising such CNP prodrugs, to their uses and to methods of treating diseases that can be treated with t…

USPTO Abstract

The present invention relates to CNP prodrugs in which the carrier is covalently and reversibly attached to the ring moiety of a CNP moiety, to pharmaceutical compositions comprising such CNP prodrugs, to their uses and to methods of treating diseases that can be treated with the CNP prodrugs of the present invention.

Drugs covered by this patent

Patent Metadata

Patent number
AU2021277638A1
Jurisdiction
AU
Classification
—
Expires
2021-12-23
Drug substance claim
No
Drug product claim
No
Assignee
Ascendis Pharma Endocrinology Division AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.